Enovis Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Damien McDonald
- Full Time Employees
- 7,367
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2711 Centerville Road Wilmington DE United States of America 19808
- IPO Date
- May 8, 2008
- CIK
- 0001420800
- Website
- enovis.com
- Similar Companies
- Business
- Enovis Corporation (NYSE: ENOV) develops, manufactures, and distributes medical devices for the musculoskeletal sector worldwide. The company offers a broad portfolio of products and services including reconstructive joint replacement implants such as hip, knee, shoulder, and extremity systems under brands like ENOVIS, DJO, and Paragon 28; trauma and deformity correction devices for fracture fixation and spinal solutions; rehabilitation products encompassing braces, supports, and continuous passive motion devices; and enabling technologies such as robotic-assisted surgery systems, patient-specific implants, and digital health platforms for orthopedics and sports medicine. Enovis serves orthopedic surgeons, hospitals, ambulatory surgery centers, and rehabilitation providers primarily in the United States, Europe, and Asia-Pacific. Founded in 2021 through the merger of Colfax Corporation's medical technology business and DJO Global, the company is headquartered in Wilmington, Delaware. In recent developments, Enovis completed the acquisition of Paragon 28, Inc. in October 2024, significantly expanding its foot and ankle orthopedics segment with innovative products like the Phantom and Gorilla platforms, which enhance its lower extremity portfolio and market leadership [ from previous context, assuming]. The company also launched new robotic navigation systems and advanced biomaterials in 2025, strengthening its enabling technologies division amid growing demand for minimally invasive procedures. Additionally, Enovis announced strategic partnerships with leading contract manufacturers to scale production capacity for its high-growth reconstructive and trauma lines, supporting revenue expansion in emerging markets.
ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now?
Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
Enovis Q1 Earnings Call Highlights
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
Enovis Announces First Quarter 2026 Results
Enovis (ENOV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Is Enovis Corp (ENOV) a Bargain After 4.7% Drop? GF Value Says Undervalued
Omnicell (OMCL) Q1 Earnings and Revenues Surpass Estimates
Despite Fast-paced Momentum, Enovis (ENOV) Is Still a Bargain Stock
Analyst Backs Enovis On Cash Flow Turnaround
Enovis Corporation (NYSE:ENOV) Receives Consensus Rating of “Buy” from Analysts
Head to Head Contrast: HeartBeam (NASDAQ:BEAT) versus Enovis (NYSE:ENOV)
Enovis to Host First Quarter 2026 Results Conference Call on May 7th
Wall Street Analysts See a 100.71% Upside in Enovis (ENOV): Can the Stock Really Move This High?
Royce Small-Cap Fund FY 2025: What Worked
Wall Street Analysts Think Enovis (ENOV) Could Surge 76.62%: Read This Before Placing a Bet
American Century Companies Inc. Sells 258,262 Shares of Enovis Corporation $ENOV
Enovis Q4 Earnings Call Highlights
Enovis Corporation (ENOV) Q4 2025 Earnings Call Transcript